{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:37:29Z","timestamp":1789612649365,"version":"build-2803163510"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiol med"],"DOI":"10.1007\/s11547-025-02140-6","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T14:10:12Z","timestamp":1762179012000},"page":"216-227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Navigating discordant findings in multimodality imaging of prostate cancer in the MRI and PSMA-PET era"],"prefix":"10.1007","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8459-8369","authenticated-orcid":false,"given":"Sungmin","family":"Woo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Masci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton S.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent P.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"de Galiza Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Laghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hebert Alberto","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"2140_CR1","unstructured":"EAU Guidelines. Edn. presented at the EAU Annual Congress Madrid 2025. ISBN 978-94-92671-29-5."},{"issue":"11","key":"2140_CR2","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.3348\/kjr.2023.0644","volume":"24","author":"LJ Wang","year":"2023","unstructured":"Wang LJ, Jinzaki M, Tan CH, Oh YT, Shinmoto H, Lee CH et al (2023) Use of imaging and biopsy in prostate cancer diagnosis: a survey from the Asian Prostate Imaging Working Group. Korean J Radiol 24(11):1102\u20131113","journal-title":"Korean J Radiol"},{"key":"2140_CR3","doi-asserted-by":"crossref","unstructured":"Expert Panel on Urological Imaging, Akin O, Woo S, Oto A, Allen BC, Avery R, et al. ACR Appropriateness Criteria\u00ae Pretreatment Detection, Surveillance, and Staging of Prostate Cancer: 2022 Update. J Am Coll Radiol. 2023; 20(5S):S187\u2013210.","DOI":"10.1016\/j.jacr.2023.02.010"},{"key":"2140_CR4","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Prostate Cancer Version 1. 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed June 2, 2025."},{"issue":"1","key":"2140_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/JU.0000000000002757","volume":"208","author":"JA Eastham","year":"2022","unstructured":"Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW et al (2022) Clinically localized prostate cancer: AUA\/ASTRO guideline, Part I: introduction, risk assessment, staging, and risk-based management. J Urol 208(1):10\u201318","journal-title":"J Urol"},{"issue":"19","key":"2140_CR6","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH et al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 378(19):1767\u20131777","journal-title":"N Engl J Med"},{"issue":"10071","key":"2140_CR7","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","volume":"389","author":"HU Ahmed","year":"2017","unstructured":"Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK et al (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389(10071):815\u2013822","journal-title":"Lancet"},{"issue":"4","key":"2140_CR8","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.eururo.2018.11.023","volume":"75","author":"M van der Leest","year":"2019","unstructured":"van der Leest M, Cornel E, Isra\u00ebl B, Hendriks R, Padhani AR, Hoogenboom M et al (2019) Head-to-head comparison of transrectal ultrasound-guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-na\u00efve men with elevated prostate-specific antigen: a large prospective multicenter clinical study. Eur Urol 75(4):570\u2013578","journal-title":"Eur Urol"},{"issue":"2","key":"2140_CR9","doi-asserted-by":"publisher","first-page":"e233337","DOI":"10.1148\/radiol.233337","volume":"312","author":"B Oerther","year":"2024","unstructured":"Oerther B, Nedelcu A, Engel H, Schmucker C, Schwarzer G, Brugger T et al (2024) Update on PI-RADS version 2.1 diagnostic performance benchmarks for prostate MRI: systematic review and meta-analysis. Radiology 312(2):e233337","journal-title":"Radiology"},{"issue":"4","key":"2140_CR10","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1016\/S1470-2045(20)30751-8","volume":"22","author":"H Hricak","year":"2021","unstructured":"Hricak H, Abdel-Wahab M, Atun R, Lette MM, Paez D, Brink JA et al (2021) Medical imaging and nuclear medicine: a lancet oncology commission. Lancet Oncol 22(4):e136\u2013e172","journal-title":"Lancet Oncol"},{"issue":"11","key":"2140_CR11","doi-asserted-by":"publisher","first-page":"e2344856","DOI":"10.1001\/jamanetworkopen.2023.44856","volume":"6","author":"H Yun","year":"2023","unstructured":"Yun H, Kim J, Gandhe A, Nelson B, Hu JC, Gulani V et al (2023) Cost-effectiveness of annual prostate MRI and potential MRI-guided biopsy after prostate-specific antigen test results. JAMA Netw Open 6(11):e2344856","journal-title":"JAMA Netw Open"},{"issue":"11","key":"2140_CR12","first-page":"1644","volume":"63","author":"L Emmett","year":"2022","unstructured":"Emmett L, Papa N, Buteau J, Ho B, Liu V, Roberts M et al (2022) The PRIMARY score: using intraprostatic 68Ga-PSMA PET\/CT patterns to optimize prostate cancer diagnosis. J Nucl Med 63(11):1644\u20131650","journal-title":"J Nucl Med"},{"key":"2140_CR13","doi-asserted-by":"publisher","first-page":"111274","DOI":"10.1016\/j.ejrad.2023.111274","volume":"170","author":"X Ren","year":"2024","unstructured":"Ren X, Nur Salihin Yusoff M, Hartini Mohd Taib N, Zhang L, Wang K (2024) 68Ga-prostate specific membrane antigen-11 PET\/CT versus multiparametric MRI in the detection of primary prostate cancer: a systematic review and head-to-head comparative meta-analysis. Eur J Radiol 170:111274","journal-title":"Eur J Radiol"},{"issue":"12","key":"2140_CR14","first-page":"1923","volume":"65","author":"I Sonni","year":"2024","unstructured":"Sonni I, Weiner AB, Doddipalli S, Deol M, Ban D, Kim HO et al (2024) Clinical, pathologic, and imaging variables associated with prostate cancer detection by PSMA PET\/CT and multiparametric MRI. J Nucl Med 65(12):1923\u20131931","journal-title":"J Nucl Med"},{"issue":"7","key":"2140_CR15","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1007\/s00330-025-11358-x","volume":"35","author":"S Woo","year":"2025","unstructured":"Woo S, Becker AS, Leithner D, Mayerhoefer ME, Friedman KP, Tong A et al (2025) Discordance between prostate MRI and PSMA-PET\/CT: the next big challenge for primary prostate tumor assessment? Eur Radiol 35(7):4043\u20134054. https:\/\/doi.org\/10.1007\/s00330-025-11358-x","journal-title":"Eur Radiol"},{"issue":"2","key":"2140_CR16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/JU.0000000000004010","volume":"212","author":"L Emmett","year":"2024","unstructured":"Emmett L, Papa N, Hope TA, Fendler W, Calais J, Burger I et al (2024) Beyond prostate imaging reporting and data system: combining magnetic resonance imaging prostate imaging reporting and data system and prostate-specific membrane antigen-positron emission tomography\/computed tomography PRIMARY score in a composite (P) score for more accurate diagnosis of clinically significant prostate cancer. J Urol 212(2):299\u2013309","journal-title":"J Urol"},{"issue":"2","key":"2140_CR17","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/jmri.25384","volume":"45","author":"MS Lee","year":"2017","unstructured":"Lee MS, Cho JY, Kim SY, Cheon GJ, Moon MH, Oh S et al (2017) Diagnostic value of integrated PET\/MRI for detection and localization of prostate cancer: comparative study of multiparametric MRI and PET\/CT. J Magn Reson Imaging 45(2):597\u2013609","journal-title":"J Magn Reson Imaging"},{"issue":"2","key":"2140_CR18","first-page":"e210091","volume":"4","author":"D Yadav","year":"2022","unstructured":"Yadav D, Hwang H, Qiao W, Upadhyay R, Chapin BF, Tang C et al (2022) 18F-fluciclovine versus PSMA pet imaging in primary tumor detection during initial staging of high-risk prostate cancer: a systematic review and meta-analysis. Radiol: Imaging Cancer 4(2):e210091","journal-title":"Radiol: Imaging Cancer"},{"issue":"2","key":"2140_CR19","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3348\/kjr.2000.1.2.110","volume":"1","author":"SB Park","year":"2000","unstructured":"Park SB, Kim JK, Choi SH, Noh HN, Ji EK, Cho KS (2000) Prostate volume measurement by TRUS using heights obtained by transaxial and midsagittal scanning: comparison with specimen volume following radical prostatectomy. Korean J Radiol 1(2):110\u2013113","journal-title":"Korean J Radiol"},{"issue":"4","key":"2140_CR20","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3348\/kjr.2019.0576","volume":"21","author":"MS Lee","year":"2020","unstructured":"Lee MS, Moon MH, Kim CK, Park SY, Choi MH, Jung SI (2020) Guidelines for transrectal ultrasonography-guided prostate biopsy: Korean society of urogenital radiology consensus statement for patient preparation, standard technique, and biopsy-related pain management. Korean J Radiol 21(4):422\u2013430","journal-title":"Korean J Radiol"},{"issue":"1","key":"2140_CR21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3348\/kjr.2010.11.1.75","volume":"11","author":"Y Zhu","year":"2010","unstructured":"Zhu Y, Chen Y, Jiang J, Wang R, Zhou Y, Zhang H (2010) Contrast-enhanced harmonic ultrasonography for the assessment of prostate cancer aggressiveness: a preliminary study. Korean J Radiol 11(1):75\u201383","journal-title":"Korean J Radiol"},{"issue":"3","key":"2140_CR22","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3348\/kjr.2014.15.3.346","volume":"15","author":"S Woo","year":"2014","unstructured":"Woo S, Kim SY, Cho JY, Kim SH (2014) Shear wave elastography for detection of prostate cancer: a preliminary study. Korean J Radiol 15(3):346\u2013355","journal-title":"Korean J Radiol"},{"issue":"2","key":"2140_CR23","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1148\/radiol.212163","volume":"305","author":"S Ghai","year":"2022","unstructured":"Ghai S, Perlis N, Atallah C, Jokhu S, Corr K, Lajkosz K et al (2022) Comparison of Micro-US and Multiparametric MRI for prostate cancer detection in biopsy-naive men. Radiology 305(2):390\u2013398","journal-title":"Radiology"},{"issue":"12","key":"2140_CR24","doi-asserted-by":"publisher","first-page":"447.e11","DOI":"10.1016\/j.urolonc.2024.06.021","volume":"42","author":"F Dagnino","year":"2024","unstructured":"Dagnino F, Avolio PP, Fasulo V, Piccolini A, Aljoulani M, Moretto S et al (2024) Clinically significant prostate cancer detection rate in biopsy-na\u00efve patients with mpMRI and microultrasound topographically discordant lesions: a single-center retrospective analysis. Urol Oncol 42(12):447.e11-447.e16","journal-title":"Urol Oncol"},{"issue":"2","key":"2140_CR25","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.eururo.2015.07.029","volume":"70","author":"M de Rooij","year":"2016","unstructured":"de Rooij M, Hamoen EHJ, Witjes JA, Barentsz JO, Rovers MM (2016) Accuracy of magnetic resonance imaging for local staging of prostate cancer: a diagnostic meta-analysis. Eur Urol 70(2):233\u2013245","journal-title":"Eur Urol"},{"issue":"1","key":"2140_CR26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s41824-020-00085-9","volume":"4","author":"S Woo","year":"2020","unstructured":"Woo S, Ghafoor S, Becker AS, Han S, Wibmer AG, Hricak H et al (2020) Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis. Eur J Hybrid Imaging 4(1):16","journal-title":"Eur J Hybrid Imaging"},{"key":"2140_CR27","doi-asserted-by":"publisher","first-page":"112033","DOI":"10.1016\/j.ejrad.2025.112033","volume":"186","author":"SV Nieuwenhove","year":"2025","unstructured":"Nieuwenhove SV, Lhommel R, Pasoglou V, Damme JV, Michoux N, Triqueneaux P et al (2025) Fast (< 30 min) \u201call-in-one\u201d whole-body MRI for TNM staging in high-risk prostate cancer (PCa): feasibility and comparison to 68Ga-prostate specific membrane antigen (PSMA)-PET\/CT. Eur J Radiol 186:112033","journal-title":"Eur J Radiol"},{"issue":"10","key":"2140_CR28","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1007\/s00259-025-07208-z","volume":"52","author":"A Kivikallio","year":"2025","unstructured":"Kivikallio A, Malaspina S, Saarinen I, Sepp\u00e4nen M, Anttinen M, Jambor I et al (2025) Prospective comparison of 18F-PSMA-1007 PET\/CT and MRI with histopathology as the reference standard for intraprostatic tumour detection and T-staging of high-risk prostate cancer. Eur J Nucl Med Mol Imaging 52(10):3709\u20133719","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2140_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41824-024-00234-4","volume":"9","author":"E Hvittfeldt","year":"2025","unstructured":"Hvittfeldt E, Hedeer F, Thimansson E, Sandeman K, Minarik D, Ingvar J et al (2025) Semi-standardized evaluation of extraprostatic extension and seminal vesicle invasion with [18F]PSMA-1007 PET\/CT: a comparison to MRI using histopathology as reference. EJNMMI Rep 9(1):1","journal-title":"EJNMMI Rep"},{"issue":"4","key":"2140_CR30","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1053\/j.semnuclmed.2019.02.007","volume":"49","author":"S Woo","year":"2019","unstructured":"Woo S, Ghafoor S, Vargas HA (2019) Contribution of radiology to staging of prostate cancer. Semin Nucl Med 49(4):294\u2013301","journal-title":"Semin Nucl Med"},{"issue":"6","key":"2140_CR31","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1007\/s00330-023-10436-2","volume":"34","author":"J Ma","year":"2024","unstructured":"Ma J, Yang Q, Ye X, Xu W, Chang Y, Chen R et al (2024) Head-to-head comparison of prostate-specific membrane antigen PET and multiparametric MRI in the diagnosis of pretreatment patients with prostate cancer: a meta-analysis. Eur Radiol 34(6):4017\u20134037","journal-title":"Eur Radiol"},{"issue":"1","key":"2140_CR32","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.eururo.2023.03.001","volume":"84","author":"KM Chow","year":"2023","unstructured":"Chow KM, So WZ, Lee HJ, Lee A, Yap DWT, Takwoingi Y et al (2023) Head-to-head comparison of the diagnostic accuracy of prostate-specific membrane antigen positron emission tomography and conventional imaging modalities for initial staging of intermediate- to high-risk prostate cancer: a systematic review and meta-analysis. Eur Urol 84(1):36\u201348","journal-title":"Eur Urol"},{"issue":"2","key":"2140_CR33","doi-asserted-by":"publisher","first-page":"W168","DOI":"10.2214\/AJR.14.12939","volume":"204","author":"S Woo","year":"2015","unstructured":"Woo S, Cho JY, Kim SY, Kim SH (2015) Extracapsular extension in prostate cancer: added value of diffusion-weighted MRI in patients with equivocal findings on T2-weighted imaging. AJR Am J Roentgenol 204(2):W168-175","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"2140_CR34","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1148\/radiol.210875","volume":"302","author":"AG Wibmer","year":"2022","unstructured":"Wibmer AG, Nikolovski I, Chaim J, Lakhman Y, Lefkowitz RA, Sala E et al (2022) Local extent of prostate cancer at MRI versus prostatectomy histopathology: associations with long-term oncologic outcomes. Radiology 302(3):595\u2013602","journal-title":"Radiology"},{"issue":"2","key":"2140_CR35","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3348\/kjr.2018.0613","volume":"20","author":"R Kim","year":"2019","unstructured":"Kim R, Kim CK, Park JJ, Kim JH, Seo SI, Jeon SS et al (2019) Prognostic significance for long-term outcomes following radical prostatectomy in men with prostate cancer: evaluation with prostate imaging reporting and data system version 2. Korean J Radiol 20(2):256\u2013264","journal-title":"Korean J Radiol"},{"issue":"8","key":"2140_CR36","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1177\/0284185115610933","volume":"57","author":"S Woo","year":"2016","unstructured":"Woo S, Cho JY, Ku JH, Kim SY, Kim SH (2016) Prostate cancer-specific mortality after radical prostatectomy: value of preoperative MRI. Acta Radiol 57(8):1006\u20131013","journal-title":"Acta Radiol"},{"issue":"6","key":"2140_CR37","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1111\/bju.16669","volume":"135","author":"L Rodriguez-Sanchez","year":"2025","unstructured":"Rodriguez-Sanchez L, Cathelineau X, De Reijke TM, Stricker P, Emberton M, Lantz A, Mi\u00f1ana L\u00f3pez B, Dominguez-Escrig JL, Bianco FJ, Salomon G, Haider A (2025) Refining partial gland ablation for localised prostate cancer: the FALCON project. BJU Int 135(6):1000\u20131009","journal-title":"BJU Int"},{"issue":"5","key":"2140_CR38","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1007\/s00259-024-07021-0","volume":"52","author":"G Huang","year":"2025","unstructured":"Huang G, Albers P, Mookerji N, Pfanner T, Hui A, Mittal R, Broomfield S, Dean L, St Martin B, Jacobsen NE, Evans H (2025) Three-dimensional spatial localization and volume estimation of prostate tumors using 18F-PSMA-1007 PET\/CT versus multiparametric MRI. Eur J Nucl Med Mol Imaging 52(5):1642\u20131648","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2140_CR39","doi-asserted-by":"publisher","first-page":"100633","DOI":"10.1016\/j.phro.2024.100633","volume":"31","author":"J Grefve","year":"2024","unstructured":"Grefve J, S\u00f6derkvist K, Gunnlaugsson A, Sandgren K, Jonsson J, Keeratijarut Lindberg A et al (2024) Histopathology-validated gross tumor volume delineations of intraprostatic lesions using PSMA-positron emission tomography\/multiparametric magnetic resonance imaging. Phys Imaging Radiat Oncol 31:100633","journal-title":"Phys Imaging Radiat Oncol"},{"issue":"11","key":"2140_CR40","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.2967\/jnumed.123.265916","volume":"64","author":"TA Hope","year":"2023","unstructured":"Hope TA, Benz M, Jiang F, Thompson D, Barbato F, Juarez R et al (2023) Do bone scans overstage disease compared with PSMA PET at initial staging? An international multicenter retrospective study with masked independent readers. J Nucl Med 64(11):1744\u20131747","journal-title":"J Nucl Med"},{"issue":"3","key":"2140_CR41","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/bju.14828","volume":"124","author":"JW Yaxley","year":"2019","unstructured":"Yaxley JW, Raveenthiran S, Nouhaud FX, Samaratunga H, Yaxley WJ, Coughlin G et al (2019) Risk of metastatic disease on 68 gallium-prostate-specific membrane antigen positron emission tomography\/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer. BJU Int 124(3):401\u2013407","journal-title":"BJU Int"},{"issue":"3","key":"2140_CR42","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/pros.21241","volume":"71","author":"S Minner","year":"2011","unstructured":"Minner S, Wittmer C, Graefen M, Salomon G, Steuber T, Haese A et al (2011) High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate 71(3):281\u2013288","journal-title":"Prostate"},{"issue":"12","key":"2140_CR43","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1007\/s00259-024-06797-5","volume":"51","author":"A Rizzo","year":"2024","unstructured":"Rizzo A, Morbelli S, Albano D, Fornarini G, Cioffi M, Laudicella R et al (2024) The Homunculus of unspecific bone uptakes associated with PSMA-targeted tracers: a systematic review-based definition. Eur J Nucl Med Mol Imaging 51(12):3753\u20133764","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"2140_CR44","doi-asserted-by":"publisher","first-page":"5337","DOI":"10.1007\/s00330-025-11514-3","volume":"35","author":"S Woo","year":"2025","unstructured":"Woo S, Becker AS, Leithner D, Charbel C, Mayerhoefer ME, Friedman KP et al (2025) PSMA-avid rib lesions in prostate cancer patients: differentiating false positives from metastatic disease. Eur Radiol 35(9):5337\u20135347. https:\/\/doi.org\/10.1007\/s00330-025-11514-3","journal-title":"Eur Radiol"},{"issue":"1","key":"2140_CR45","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40644-020-00300-7","volume":"20","author":"BF de Galiza","year":"2020","unstructured":"de Galiza BF, Queiroz MA, Nunes RF, Costa LB, Zaniboni EC, Marin JFG et al (2020) Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings. Cancer Imaging 20(1):23","journal-title":"Cancer Imaging"},{"issue":"5","key":"2140_CR46","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.eururo.2023.06.008","volume":"84","author":"RA Werner","year":"2023","unstructured":"Werner RA, Hartrampf PE, Fendler WP, Serfling SE, Derlin T, Higuchi T et al (2023) Prostate-specific membrane antigen reporting and data system version 2.0. Eur Urol 84(5):491\u2013502","journal-title":"Eur Urol"},{"issue":"6","key":"2140_CR47","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.euo.2018.11.007","volume":"2","author":"SP Thang","year":"2019","unstructured":"Thang SP, Violet J, Sandhu S, Iravani A, Akhurst T, Kong G et al (2019) Poor outcomes for patients with metastatic castration-resistant prostate cancer with low prostate-specific membrane antigen (PSMA) expression deemed ineligible for 177Lu-labelled PSMA radioligand therapy. Eur Urol Oncol 2(6):670\u2013676","journal-title":"Eur Urol Oncol"},{"issue":"10276","key":"2140_CR48","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC et al (2021) [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 397(10276):797\u2013804","journal-title":"Lancet"},{"issue":"11","key":"2140_CR49","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.3348\/kjr.2024.0439","volume":"25","author":"SJ Na","year":"2024","unstructured":"Na SJ, Ha S, Kim IH, Lee JY, O JH (2024) Description of FDG and prostate-specific membrane antigen PET\/CT findings in Korean patients with advanced metastatic castration-resistant prostate cancer. Korean J Radiol 25(11):1022\u20131028","journal-title":"Korean J Radiol"},{"issue":"2","key":"2140_CR50","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2967\/jnumed.124.268275","volume":"66","author":"C Madsen","year":"2025","unstructured":"Madsen C, Fugl\u00f8 D, Pedersen M, Broholm R, \u00d8stergren PB, Bisbjerg R et al (2025) Prospective Head-to-Head Comparison of 18F-PSMA PET\/CT and 18F-NaF PET\/CT for Assessing Bone Metastases in 160 Patients with Newly Diagnosed High-Risk Prostate Cancer. J Nucl Med 66(2):223\u2013229","journal-title":"J Nucl Med"},{"issue":"1","key":"2140_CR51","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1148\/radiol.13130625","volume":"271","author":"HA Vargas","year":"2014","unstructured":"Vargas HA, Wassberg C, Fox JJ, Wibmer A, Goldman DA, Kuk D et al (2014) Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology 271(1):220\u2013229","journal-title":"Radiology"},{"issue":"14","key":"2140_CR52","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1158\/1078-0432.CCR-11-0815","volume":"17","author":"CJ Ryan","year":"2011","unstructured":"Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ et al (2011) Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res 17(14):4854\u20134861","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2140_CR53","doi-asserted-by":"publisher","first-page":"e233460","DOI":"10.1148\/radiol.233460","volume":"312","author":"PH Kuo","year":"2024","unstructured":"Kuo PH, Morris MJ, Hesterman J, Kendi AT, Rahbar K, Wei XX et al (2024) Quantitative 68Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following 177Lu-PSMA-617 (VISION trial). Radiology 312(2):e233460","journal-title":"Radiology"},{"issue":"5","key":"2140_CR54","doi-asserted-by":"publisher","first-page":"678","DOI":"10.2967\/jnumed.119.233817","volume":"61","author":"S Fanti","year":"2020","unstructured":"Fanti S, Hadaschik B, Herrmann K (2020) Proposal for systemic-therapy response-assessment criteria at the time of PSMA PET\/CT imaging: the PSMA PET progression criteria. J Nucl Med 61(5):678\u2013682","journal-title":"J Nucl Med"},{"issue":"11","key":"2140_CR55","first-page":"1651","volume":"63","author":"A Gafita","year":"2022","unstructured":"Gafita A, Rauscher I, Weber M, Hadaschik B, Wang H, Armstrong WR et al (2022) Novel framework for treatment response evaluation using PSMA PET\/CT in Patients with metastatic castration-resistant prostate cancer (RECIP 1.0): An international multicenter study. J Nucl Med 63(11):1651\u20131658","journal-title":"J Nucl Med"},{"issue":"3","key":"2140_CR56","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s11547-018-0955-7","volume":"124","author":"G Petralia","year":"2019","unstructured":"Petralia G, Padhani AR, Pricolo P, Zugni F, Martinetti M, Summers PE et al (2019) Whole-body magnetic resonance imaging (WB-MRI) in oncology: recommendations and key uses. Radiol Med 124(3):218\u2013233","journal-title":"Radiol Med"},{"issue":"1","key":"2140_CR57","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s40644-020-00350-x","volume":"20","author":"P Pricolo","year":"2020","unstructured":"Pricolo P, Ancona E, Summers P, Abreu-Gomez J, Alessi S, Jereczek-Fossa BA et al (2020) Whole-body magnetic resonance imaging (WB-MRI) reporting with the METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P): inter-observer agreement between readers of different expertise levels. Cancer Imaging 20(1):77","journal-title":"Cancer Imaging"},{"issue":"1","key":"2140_CR58","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.eururo.2016.05.033","volume":"71","author":"AR Padhani","year":"2017","unstructured":"Padhani AR, Lecouvet FE, Tunariu N, Koh DM, De Keyzer F, Collins DJ et al (2017) METastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer. Eur Urol 71(1):81\u201392","journal-title":"Eur Urol"},{"issue":"4","key":"2140_CR59","doi-asserted-by":"publisher","first-page":"e391","DOI":"10.1016\/j.clgc.2019.12.010","volume":"18","author":"S Yoshida","year":"2020","unstructured":"Yoshida S, Takahara T, Ishii C, Arita Y, Waseda Y, Kijima T et al (2020) METastasis reporting and data system for prostate cancer as a prognostic imaging marker in castration-resistant prostate cancer. Clin Genitourin Cancer 18(4):e391\u2013e396","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"2140_CR60","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3390\/diagnostics11040663","volume":"11","author":"S Han","year":"2021","unstructured":"Han S, Woo S, Kim YI, Lee JL, Wibmer AG, Schoder H et al (2021) Concordance between response assessment using prostate-specific membrane antigen PET and serum prostate-specific antigen levels after systemic treatment in patients with metastatic castration resistant prostate cancer: a systematic review and meta-analysis. Diagnostics (Basel) 11(4):663","journal-title":"Diagnostics (Basel)"},{"issue":"24","key":"2140_CR61","first-page":"00238","volume":"S2588\u20139311","author":"J Van Damme","year":"2024","unstructured":"Van Damme J, Tombal B, Michoux N, Van Nieuwenhove S, Pasoglou V, Triqueneaux P et al (2024) Value of whole-body magnetic resonance imaging using the MET-RADS-P criteria for assessing the response to intensified androgen deprivation therapy in metastatic hormone-na\u00efve and castration-resistant prostate cancer. Eur Urol Oncol S2588\u20139311(24):00238\u201300244","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"2140_CR62","doi-asserted-by":"publisher","first-page":"e938","DOI":"10.1200\/OP.21.00816","volume":"18","author":"LM Ruppert","year":"2022","unstructured":"Ruppert LM, Cohn ED, Keegan NM, Bacharach A, Woo S, Gillis T et al (2022) Spine pain and metastatic prostate cancer: defining the contribution of nonmalignant etiologies. JCO Oncol Pract 18(6):e938\u2013e947","journal-title":"JCO Oncol Pract"},{"issue":"18","key":"2140_CR63","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1158\/1078-0432.CCR-24-1096","volume":"30","author":"CJ Sweeney","year":"2024","unstructured":"Sweeney CJ, Petry R, Xu C, Childress M, He J, Fabrizio D et al (2024) Circulating tumor DNA assessment for treatment monitoring adds value to PSA in metastatic castration-resistant prostate cancer. Clin Cancer Res 30(18):4115\u20134122","journal-title":"Clin Cancer Res"},{"key":"2140_CR64","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.urology.2016.11.017","volume":"102","author":"DJ Bryk","year":"2017","unstructured":"Bryk DJ, Llukani E, Taneja SS, Rosenkrantz AB, Huang WC, Lepor H (2017) The role of ipsilateral and contralateral transrectal ultrasound-guided systematic prostate biopsy in men with unilateral magnetic resonance imaging lesion undergoing magnetic resonance imaging-ultrasound fusion-targeted prostate biopsy. Urology 102:178\u2013182","journal-title":"Urology"},{"issue":"4","key":"2140_CR65","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41391-018-0062-9","volume":"21","author":"MA Coker","year":"2018","unstructured":"Coker MA, Glaser ZA, Gordetsky JB, Thomas JV, Rais-Bahrami S (2018) Targets missed: predictors of MRI-targeted biopsy failing to accurately localize prostate cancer found on systematic biopsy. Prostate Cancer Prostatic Dis 21(4):549\u2013555","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"2140_CR66","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1148\/radiol.2019180712","volume":"291","author":"M Zhang","year":"2019","unstructured":"Zhang M, Milot L, Khalvati F, Sugar L, Downes M, Baig SM et al (2019) Value of increasing biopsy cores per target with cognitive MRI-targeted transrectal US prostate biopsy. Radiology 291(1):83\u201389","journal-title":"Radiology"},{"issue":"3","key":"2140_CR67","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.eururo.2022.01.008","volume":"82","author":"WG Brisbane","year":"2022","unstructured":"Brisbane WG, Priester AM, Ballon J, Kwan L, Delfin MK, Felker ER et al (2022) Targeted prostate biopsy: umbra, penumbra, and value of perilesional sampling. Eur Urol 82(3):303\u2013310","journal-title":"Eur Urol"},{"issue":"11","key":"2140_CR68","doi-asserted-by":"publisher","first-page":"7481","DOI":"10.1007\/s00330-024-10792-7","volume":"34","author":"A Ponsiglione","year":"2024","unstructured":"Ponsiglione A, Brembilla G, Cuocolo R, Gutierrez P, Moreira AS, Pecoraro M et al (2024) ESR essentials: using the right scoring system in prostate MRI-practice recommendations by ESUR. Eur Radiol 34(11):7481\u20137491","journal-title":"Eur Radiol"},{"issue":"6","key":"2140_CR69","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.euo.2021.01.003","volume":"4","author":"V Panebianco","year":"2021","unstructured":"Panebianco V, Villeirs G, Weinreb JC, Turkbey BI, Margolis DJ, Richenberg J et al (2021) Prostate magnetic resonance imaging for local recurrence reporting (PI-RR): international consensus -based guidelines on multiparametric magnetic resonance imaging for prostate cancer recurrence after radiation therapy and radical prostatectomy. Eur Urol Oncol 4(6):868\u2013876","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"2140_CR70","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.euo.2023.04.007","volume":"6","author":"F Giganti","year":"2023","unstructured":"Giganti F, Dickinson L, Orczyk C, Haider A, Freeman A, Emberton M et al (2023) Prostate imaging after focal ablation (PI-FAB): a proposal for a scoring system for multiparametric MRI of the prostate after focal therapy. Eur Urol Oncol 6(6):629\u2013634","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"2140_CR71","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2024.02.001","volume":"85","author":"A Light","year":"2024","unstructured":"Light A, Mayor N, Cullen E, Kirkham A, Padhani AR, Arya M et al (2024) The transatlantic recommendations for prostate gland evaluation with magnetic resonance imaging after focal therapy (TARGET): a systematic review and international consensus recommendations. Eur Urol 85(5):466\u2013482","journal-title":"Eur Urol"},{"key":"2140_CR72","doi-asserted-by":"publisher","first-page":"112028","DOI":"10.1016\/j.ejrad.2025.112028","volume":"186","author":"AM Pausch","year":"2025","unstructured":"Pausch AM, Elsner C, Rupp NJ, Eberli D, H\u00f6tker AM (2025) Comparative analysis of TARGET and PI-FAB scores in mpMRI surveillance after HIFU therapy for localized prostate cancer. Eur J Radiol 186:112028","journal-title":"Eur J Radiol"},{"issue":"2","key":"2140_CR73","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.acra.2024.09.051","volume":"32","author":"OT Esengur","year":"2025","unstructured":"Esengur OT, Gelikman DG, Law YM, Yilmaz EC, Harmon SA, Merino MJ et al (2025) Comparison of transatlantic recommendations for prostate gland evaluation with MRI after focal therapy (TARGET) and prostate imaging after focal ablation (PI-FAB) for detecting recurrent prostate cancer at prostate MRI. Acad Radiol 32(2):855\u2013863","journal-title":"Acad Radiol"},{"issue":"supplement 1","key":"2140_CR74","first-page":"P1241","volume":"64","author":"M Jafarvand","year":"2023","unstructured":"Jafarvand M, Farolfi A, Benz M, Djaileb L, Mei R, Czernin J et al (2023) PSMA PET\/CT for prostate cancer patients after focal therapy: a single center retrospective analysis. J Nucl Med 64(supplement 1):P1241","journal-title":"J Nucl Med"},{"issue":"1","key":"2140_CR75","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13550-024-01097-3","volume":"14","author":"CE Popescu","year":"2024","unstructured":"Popescu CE, Zhang B, Sartoretti T, Spielhofer N, Skawran S, Heimer J et al (2024) Evaluating the biodistribution for [68Ga]Ga-PSMA-11 and [18F]F-PSMA-1007 PET\/CT with an inter- and intrapatient based analysis. EJNMMI Res 14(1):36","journal-title":"EJNMMI Res"},{"issue":"1","key":"2140_CR76","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13550-024-01190-7","volume":"15","author":"J Heilinger","year":"2025","unstructured":"Heilinger J, Roth KS, Weis H, Fink A, Weindler J, Dietlein F et al (2025) Do you know your PSMA-tracer? Variability in the biodistribution of different PSMA ligands and its potential impact on defining PSMA-positivity prior to PSMA-targeted therapy. EJNMMI Res 15(1):4","journal-title":"EJNMMI Res"},{"issue":"5","key":"2140_CR77","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J et al (2023) Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2). Eur Urol 83(5):405\u2013412","journal-title":"Eur Urol"},{"issue":"5","key":"2140_CR78","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40336-024-00631-6","volume":"12","author":"S Woo","year":"2024","unstructured":"Woo S, Freedman D, Becker AS, Leithner D, Mayerhoefer ME, Friedman KP et al (2024) Equivocal bone lesions on PSMA PET\/CT: systematic review and meta-analysis on their prevalence and malignancy rate. Clin Transl Imaging 12(5):485\u2013500","journal-title":"Clin Transl Imaging"},{"issue":"4","key":"2140_CR79","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","volume":"40","author":"A Afshar-Oromieh","year":"2013","unstructured":"Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA et al (2013) PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 40(4):486\u2013495","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"2140_CR80","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s00259-016-3594-z","volume":"44","author":"MT Freitag","year":"2017","unstructured":"Freitag MT, Radtke JP, Afshar-Oromieh A, Roethke MC, Hadaschik BA, Gleave M et al (2017) Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET\/CT and PET\/MRI: comparison with mpMRI integrated in simultaneous PET\/MRI. Eur J Nucl Med Mol Imaging 44(5):776\u2013787","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2140_CR81","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13550-022-00913-y","volume":"12","author":"ML Donswijk","year":"2022","unstructured":"Donswijk ML, Wondergem M, de van der Wit Veen L, Bruin NM, van Leeuwen PJ, van der Poel HG, Stokkel MP, Vogel WV (2022) Effects of furosemide and tracer selection on urinary activity and peri-bladder artefacts in PSMA PET\/CT: a single-centre retrospective study. EJNMMI Res 12(1):42","journal-title":"EJNMMI Res"},{"issue":"5","key":"2140_CR82","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.euo.2022.06.007","volume":"5","author":"S Kotamarti","year":"2022","unstructured":"Kotamarti S, Gupta RT, Wang B, S\u00e9guier D, Michael Z, Zhang D et al (2022) Reconciling discordance between prostate biopsy histology and magnetic resonance imaging suspicion - implementation of a quality improvement protocol of imaging re-review and reverse-fusion target analysis. Eur Urol Oncol 5(5):483\u2013493","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"2140_CR83","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3348\/kjr.2020.1369","volume":"23","author":"S Lee","year":"2022","unstructured":"Lee S, Oh YT, Kim HM, Jung DC, Hong H (2022) Imaging patterns of Bacillus Calmette-Gu\u00e9rin-related granulomatous prostatitis based on multiparametric MRI. Korean J Radiol 23(1):60\u201367","journal-title":"Korean J Radiol"},{"issue":"24","key":"2140_CR84","first-page":"00180","volume":"S2588\u20139311","author":"F Ridouani","year":"2024","unstructured":"Ridouani F, Alberto Vargas H, Holzwanger DJ, Sch\u00f6der H, Waters E, Petre EN et al (2024) Clinical, imaging, and technical factors associated with successful genomic profiling of bone biopsy tissue in prostate cancer. Eur Urol Oncol S2588\u20139311(24):00180\u201300189","journal-title":"Eur Urol Oncol"},{"issue":"7","key":"2140_CR85","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.1007\/s00330-022-08536-6","volume":"32","author":"R Donners","year":"2022","unstructured":"Donners R, Figueiredo I, Tunariu N, Blackledge M, Koh DM, de la Maza LDFM et al (2022) Multiparametric bone MRI can improve CT-guided bone biopsy target selection in cancer patients and increase diagnostic yield and feasibility of next-generation tumour sequencing. Eur Radiol 32(7):4647\u20134656","journal-title":"Eur Radiol"},{"key":"2140_CR86","doi-asserted-by":"publisher","first-page":"110955","DOI":"10.1016\/j.ejrad.2023.110955","volume":"165","author":"AS Becker","year":"2023","unstructured":"Becker AS, Giganti F, Purysko AS, Fainberg J, Vargas HA, Woo S (2023) Taking PI-QUAL beyond the prostate: towards a standardized radiological image quality score (RI-QUAL). Eur J Radiol 165:110955","journal-title":"Eur J Radiol"},{"issue":"11","key":"2140_CR87","doi-asserted-by":"publisher","first-page":"7068","DOI":"10.1007\/s00330-024-10795-4","volume":"34","author":"M de Rooij","year":"2024","unstructured":"de Rooij M, Allen C, Twilt JJ, Thijssen LCP, Asbach P, Barrett T et al (2024) PI-QUAL version 2: an update of a standardised scoring system for the assessment of image quality of prostate MRI. Eur Radiol 34(11):7068\u20137079","journal-title":"Eur Radiol"},{"issue":"4","key":"2140_CR88","doi-asserted-by":"publisher","first-page":"823","DOI":"10.2214\/AJR.18.20295","volume":"212","author":"AM H\u00f6tker","year":"2019","unstructured":"H\u00f6tker AM, Dappa E, Mazaheri Y, Ehdaie B, Zheng J, Capanu M et al (2019) The influence of background signal intensity changes on cancer detection in prostate MRI. AJR Am J Roentgenol 212(4):823\u2013829","journal-title":"AJR Am J Roentgenol"}],"container-title":["La radiologia medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-025-02140-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11547-025-02140-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-025-02140-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T21:03:59Z","timestamp":1771967039000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11547-025-02140-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":88,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["2140"],"URL":"https:\/\/doi.org\/10.1007\/s11547-025-02140-6","relation":{},"ISSN":["1826-6983"],"issn-type":[{"value":"1826-6983","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"28 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kent P. Friedman is a coinvestigator on \u201cOptimizing timing of rhPSMA-7.3 (18F), for assessing site(s) of recurrent disease following radical prostatectomy\u201d (PI Herbert Lepor) but does not receive any salary support and was unrelated to the current work. Damiano Caruso is an editor of this journal but had no involvement in the peer review process. The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This work did not involve research of human or animal subjects as it was a review of the existing literature and therefore did not require ethics approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval\/Consent to participate\/Consent to publish"}}]}}